Stocks and Investing Stocks and Investing
Thu, January 19, 2012

SIGMA-ALDRICH (NASDAQ:SIAL), Up By 5.93% ($3.73) From $62.860 After BUYINS.NET Report Predicted Strength Before Earnings


Published on 2012-01-19 11:41:08 - WOPRAI
  Print publication without navigation


January 19, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Monday, December 26th 2011 stating that SIGMA-ALDRICH (NASDAQ:SIAL) was expected to be Up Before its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=sial&id=225881

At the time this story was written, SIGMA-ALDRICH (NASDAQ:SIAL) is Up By 5.93% ($3.73) From $62.860 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

SIGMA-ALDRICH (NASDAQ:SIAL) - Sigma-Aldrich Corporation, together with its subsidiaries, develops, manufactures, purchases, and distributes a range of chemicals, biochemicals, and equipment worldwide. Its chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, and pharmaceutical development; and as key components in pharmaceutical, diagnostic, and other high technology manufacturing. The company offers biological buffers, cell culture reagents, biochemicals, chemicals, solvents, and other reagents and kits. It also sells organic chemicals, analytical reagents, chromatography and other laboratory consumables, reference materials, and high-purity products. In addition, the company supplies immunochemical, molecular biology, cell biology, proteomic, genomic, transgenic, and other life science products; and organic chemicals and biochemicals used in development and production. It sells its products to universities, commercial laboratories, non-profit organizations, governmental institutions, and hospitals, as well as industrial, pharmaceutical research, biotechnology, diagnostic, chemical, and electronics companies. The company was founded in 1951 and is based in St. Louis, Missouri.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. SIGMA-ALDRICH (NASDAQ:SIAL) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net

Contributing Sources